Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q2 2013 · 10-Q
Revenue$183.00K$183.00K+18,200.0% vs Q2 2012 Net Income-$319.00K-$319.00KN/M vs Q2 2012 EPS Diluted$0.00$0.00N/M vs Q2 2012 Gross Profit$60,000+5,900.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
Operating Cash Flowderived$20,000N/M Margins · derivedGross margin32.8%−67.2 pt vs Q2 2012
Operating margin-76.5%+102923.5 pt vs Q2 2012
Net margin-174.3%+239325.7 pt vs Q2 2012
ended Jun 30, 2013 · filed Dec 12, 2014 · 530 d after period end